Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma
Open Access
- 15 October 2012
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 53 (12), 1829-1835
- https://doi.org/10.2967/jnumed.112.106500
Abstract
18F-FDG PET/CT allows the direct measurement of metabolic tumor burden in a variety of different malignancies. The aim of this study was to assess whether metabolic tumor volume (MTV) determined by 18F-FDG PET/CT could be used in the prediction of progression-free and overall survival in multiple myeloma patients. Methods: Forty-seven patients (18 women, 29 men; mean age ± SD, 63 ± 11 y) with stage IIIA disease who had undergone whole-body 18F-FDG PET/CT were retrospectively evaluated. Images underwent a 3-dimensional region-of-interest analysis including all focal lesions with a maximum standardized uptake value > 2.5. The MTV of each lesion was calculated using an automated contouring program based on the standardized uptake value and developed with a threshold of 40% of the maximum standardized uptake value. The total MTV of each patient was defined as the sum of metabolic volume of all focal lesions. Patients were treated and then subjected to a mean follow-up period of 24 mo. Results: In the 47 patients studied, MTV range was 1.3–316.3 mL, with a median of 23.7 mL. A direct, significant correlation was found between MTV and the percentage of diffuse infiltration of bone marrow by plasma cells (r = 0.46, P = 0.006), whereas hemoglobin levels were inversely correlated with MTV (r = −0.56, P = 0.0001). At follow-up, patients who developed progressive disease (n = 18) showed a significantly higher MTV (74.7 ± 19.3 vs. 29.8 ± 5.1 mL, P = 0.009) than patients without progressive disease (n = 29). Furthermore, patients who died of myeloma (n = 9) had a significantly higher MTV (123.2 ± 30.6 vs. 28.9 ± 4.2 mL, P = 0.0001) than survivors (n = 38). No differences in age, plasma cell infiltration, M protein, albumin, β2-microglobulin, performance status, International Staging System score, and presence or absence of a bone marrow transplant were found between groups. The MTV cutoff level was determined by receiver-operating-characteristic curve analysis, and the best discriminative value found for predicting progression-free and overall survival was 42.2 and 77.6 mL, respectively. By Kaplan–Meier analysis and log-rank testing, progression-free and overall survival at follow-up were significantly better in patients showing an MTV lower than the cutoff than in those having an MTV higher than the cutoff (χ2 = 3.9, P = 0.04, and χ2 = 56.3, P < 0.0001, respectively). Conclusion: The direct measurement of tumor burden obtained by calculating MTV on 18F-FDG PET/CT images may be used in the prediction of progression-free and overall survival in myeloma patients.Keywords
This publication has 33 references indexed in Scilit:
- Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease AssessmentMolecular Imaging & Biology, 2010
- Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal CancerClinical Cancer Research, 2009
- Metabolic Tumor Volume Predicts for Recurrence and Death in Head-and-Neck CancerInternational Journal of Radiation Oncology*Biology*Physics, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Positron Emission Tomography/Computed Tomography for Target Delineation in Head and Neck CancersSeminars in Nuclear Medicine, 2008
- Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung CancerInternational Journal of Radiation Oncology*Biology*Physics, 2007
- The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging systemEuropean Journal Of Cancer, 2006
- Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma FoundationThe Hematology Journal, 2003
- Segmentation of lung lesion volume by adaptive positron emission tomography image thresholdingCancer, 1997
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975